Cambiar Investors LLC increased its holdings in shares of Smith & Nephew plc (NYSE:SNN) by 10.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,935,389 shares of the medical equipment provider’s stock after acquiring an additional 537,369 shares during the period. Smith & Nephew makes up approximately 3.3% of Cambiar Investors LLC’s portfolio, making the stock its 11th biggest holding. Cambiar Investors LLC owned 1.36% of Smith & Nephew worth $207,798,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in SNN. Bessemer Group Inc. lifted its position in shares of Smith & Nephew by 400.2% in the third quarter. Bessemer Group Inc. now owns 2,781 shares of the medical equipment provider’s stock valued at $102,000 after acquiring an additional 2,225 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Smith & Nephew in the fourth quarter valued at $126,000. Lbmc Investment Advisors LLC purchased a new stake in shares of Smith & Nephew in the third quarter valued at $206,000. First Allied Advisory Services Inc. acquired a new position in Smith & Nephew in the third quarter valued at $247,000. Finally, Quantbot Technologies LP increased its stake in Smith & Nephew by 270.0% in the second quarter. Quantbot Technologies LP now owns 7,277 shares of the medical equipment provider’s stock valued at $253,000 after purchasing an additional 5,310 shares during the last quarter. 6.59% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Smith & Nephew plc (NYSE:SNN) traded up $0.44 during midday trading on Wednesday, hitting $35.78. The company had a trading volume of 333,709 shares, compared to its average volume of 606,289. Smith & Nephew plc has a 1-year low of $30.16 and a 1-year high of $40.43. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 2.03.
SNN has been the subject of several analyst reports. Zacks Investment Research upgraded Smith & Nephew from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th. Morgan Stanley lowered Smith & Nephew from an “overweight” rating to an “equal weight” rating in a research note on Monday, December 11th. Canaccord Genuity restated a “buy” rating and set a $45.00 price target on shares of Smith & Nephew in a research note on Friday, January 5th. JPMorgan Chase & Co. upgraded Smith & Nephew from a “neutral” rating to an “overweight” rating in a research note on Thursday, January 25th. Finally, ValuEngine lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Smith & Nephew has a consensus rating of “Hold” and an average price target of $44.00.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/cambiar-investors-llc-purchases-537369-shares-of-smith-nephew-plc-snn.html.
About Smith & Nephew
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.